High-throughput discovery of novel antibiotics against nontuberculous mycobacteria

针对非结核分枝杆菌的新型抗生素的高通量发现

• 批准号: 10061834
• 金额: $ 44.57万
• 依托单位: BACTOBIO LTD
• 依托单位国家: 英国
• 项目类别: Collaborative R&D
• 财政年份: 2023
• 资助国家: 英国
• 起止时间: 2023 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=10061834
• 关键词: throughput; discovery; novel; antibiotics; against

Nontuberculous mycobacteria(NTM) are a group of bacteria responsible for over 100,000 deadly lung infections annually. Infections predominantly impact immunocompromised patients and the cystic fibrosis(CF) community, with ?10% of people with CF infected. High levels of intrinsic antimicrobial resistance and persistent infections have made these pathogens hard and often impossible to treat.Current NTM therapeutic options involve intensive multi-drug regimens with low efficacy, severe side effects and high treatment burden. Average treatment costs range between £4k-£16k/year with additional healthcare spend of up to £10k. With increasing rates of resistance and no new antibiotic classes entering the market in the last 40 years, there is an urgent need for new antibiotic treatment options to combat NTM infections. The project aims to improve the clinical outlook, life expectancy and quality of life of NTM patients in the UK and globally.80% of all antibiotics and 4 of 5 major classes used to treat NTM today derive from the ~1% of soil microbes which can be readily cultured in the laboratory. This bioresource has now been exhausted for novel antibiotics whilst efforts to discover new synthetic solutions have failed to fill the gap and have proven costly to develop(?£1Bn per novel antibiotic). Accessing the remaining 99% of uncultured microbes represents the best opportunity to discover new antibiotics.Bactobio has developed a platform that combines synthetic biology, next-generation sequencing, and machine learning to culture previously unculturable microbes. So far, we have gained exclusive access to ?1,800 species. In this project, we will expand and screen our in-house library of unique microbial species for production of novel antibiotics against NTM. We have set an ambitious goal to find 3 promising antibiotic chemical compound candidates targeting NTM, thereby providing a compelling case for further investment from the pharmaceutical industry through licensing deals valued at ?£100Mn per compound.

非结核分枝杆菌（NTM）是一组每年造成超过10万例致命肺部感染的细菌。感染主要影响免疫功能低下的患者和囊性纤维化（CF）社区，与？10%的CF感染者。高水平的内在抗菌素耐药性和持续感染使这些病原体难以治疗，通常无法治疗。目前的NTM治疗方案涉及密集的多药方案，疗效低，副作用严重，治疗负担高。平均治疗费用在4k-16 k英镑/年之间，额外的医疗保健支出高达10 k英镑。随着耐药性的增加，在过去的40年里没有新的抗生素进入市场，迫切需要新的抗生素治疗方案来对抗NTM感染。该项目旨在改善英国和全球NTM患者的临床前景，预期寿命和生活质量。目前用于治疗NTM的所有抗生素中的80%和5个主要类别中的4个来自约1%的土壤微生物，这些微生物可以在实验室中容易地培养。这种生物资源现在已经耗尽了新的抗生素，而努力发现新的合成解决方案未能填补差距，并已证明昂贵的开发（？每种新型抗生素10亿英镑）。剩余99%的未培养微生物是发现新抗生素的最佳机会。Bactobio开发了一个平台，结合合成生物学，下一代测序和机器学习来培养以前无法培养的微生物。到目前为止，我们已经获得了独家访问？1,800种。在这个项目中，我们将扩大和筛选我们内部的独特微生物物种库，用于生产针对NTM的新型抗生素。我们已经制定了一个雄心勃勃的目标，找到3个有前途的抗生素化合物候选人针对NTM，从而提供了一个令人信服的情况下，进一步投资从制药行业通过许可交易价值？每种化合物100 Mn英镑。